CD4 and melanoma: We have also confirmed the induction of an antitumor immune response in vaccine and immunotherapy settings, with critical involvement of NK cells, CD4+ and CD8+ T cells, when our vector is used in immunocompetent C57BL/6 mice and B16-F10 mouse melanoma cells (Medrano et al., 2016).